Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Pabst, Tobias; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rufer, Axel; Renner, Christoph; Driessen, Christoph (2021). P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). Clinical lymphoma, myeloma and leukemia, 21(Suppl. 2), S165-S165. Elsevier 10.1016/S2152-2650(21)02354-5
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S2152265021023545-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (87kB) |
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Pabst, Thomas Niklaus, Novak, Urban |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2152-2650 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Rebeka Gerber |
Date Deposited: |
17 Jan 2023 10:53 |
Last Modified: |
17 Jan 2023 23:27 |
Publisher DOI: |
10.1016/S2152-2650(21)02354-5 |
BORIS DOI: |
10.48350/176958 |
URI: |
https://boris.unibe.ch/id/eprint/176958 |
Actions (login required)
 |
Edit item |